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Since their publication in 2000, the Newcastle
protocols1 on head-up tilt testing in the diagnosis
of vasovagal syncope and related disorders have
provided a succinct and practical guide for those
setting up and managing syncope services incor-
porating the investigation and management of
neurally mediated disorders. In the intervening
seven years our protocols have changed in line with
published evidence on new methodologies and
management strategies and our own clinical
experience (with more than 1000 new and 3000
review patients seen each year at our specialist
syncope facility), so the time is ripe for a fresh
approach. Much of this information is available in
a number of important papers on syncope manage-
ment2–4 and pacing indications5 6; while compre-
hensive, these guidelines are also lengthy and
inclusive of competing methodologies. They are
therefore less accessible for those needing a more
prescriptive and pragmatic view. The Newcastle
protocols 2008 presented below provide such a
view. Since these protocols reflect current clinical
practice, an exhaustive review of the evidence base
for the various methodologies presented will not be
attempted—the reader should consult the more
detailed papers referenced if this is required.2–6
Similarly some prior knowledge of the subject
matter is assumed, in particular the differentiation
between syncope and non-syncopal loss of con-
sciousness as well as the diagnostic process leading
to head-up tilt table testing.2 3 The protocols are
designed for adults with syncope (defined as
transient loss of consciousness with loss of
postural tone and spontaneous and complete
recovery), with no upper limit on age.
STYLE
The Newcastle protocols 2008 are intended to
complement rather than reproduce the originals, so
only new information will be presented, occasion-
ally with a summarised version of the old to aid
clarity. Still-valid detailed prior information will be
referenced to the 2000 version.1 The original
protocols deliberately omitted reference to the
management of the neurally mediated disorders,
but a succinct and practical guide to treatment will
also be presented below.
INDICATIONS FOR HEAD-UP TILT TABLE TESTING
These remain largely unchanged, though there is
international consensus that the test is largely
unnecessary for the majority of patients with
vasovagal syncope. None the less, tilt testing is
cheap, safe and well tolerated and has enormous
clinical utility in the appropriate clinical circum-
stances. Given an appropriate and detailed clinical
history, normal cardiovascular examination (or
echocardiogram if available) and normal surface
electrocardiogram (ECG), there is a very high
probability that the individual will have neurally
mediated syncope and can be managed with no
further investigations.2 3 Where the history is
atypical or absent (for example, in those with
cognitive impairment), where there is a driving or
occupational imperative for a formal diagnosis, or
where the patient has suffered injury, head-up tilt
table testing should be considered.1 Head-up tilt
table testing may also occasionally be helpful in the
investigation of unexplained drop attacks.7 Other
indications are unchanged.1
CONTRAINDICATIONS AND SAFETY MATTERS
Contraindications to head-up tilt table testing are
few but include critical mitral stenosis and left
ventricular outflow tract obstruction and severe
proximal cerebral or coronary arterial disease.1 The
test remains remarkably safe at all ages,8 9 though
there are isolated reports of ventricular tachyar-
rhythmias10 11 and myocardial infarction12 during
tilt testing. The majority of adverse events occur in
the context of isoproterenol-provoked tilt.10 12
Though without an evidence base, it is our practice
to limit significant hypotension during tilt (arbi-
trarily defined as a fall in systolic blood pressure of
.50% from baseline, or less than 90 mm Hg) to no
more than three minutes in older more frail
patients with known ischaemic heart or cerebro-
vascular disease. Consensus guidelines state that
cardiopulmonary resuscitation equipment and
expertise be immediately to hand2 3—given the
safety profile of the test, this might legitimately be
questioned, particularly for unprovoked and non-
isoproterenol testing.
HEAD-UP TILT TEST METHODOLOGY
Patients are not required to fast and should
continue suspected culprit medications on the
day of testing. If suspected culprit medications
are discontinued before testing, we prefer to gauge
the clinical response before proceeding to tilt. The
procedure should be explained to the patient, who
remains supine for 10 minutes, or 20 minutes if
cannulated. The 10-minute rest is a change from
the previous protocols 1 and reflects our experience
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with the shorter rest with no fall in positivity rates. Lower limb
movements must be avoided to enhance the venous pooling
needed to provoke the vasovagal episode.
Equipment, monitoring and environment
These are essentially unchanged. A footplate support-type tilt
table capable of tilting upright to a calibrated angle of 70u,1 and
capable of rapid movements from upright to supine within
10 seconds is necessary, along with continuous ECG and blood
pressure monitoring, which should be of the beat-to-beat
variety. Since the original protocols were published, a number
of devices for recording beat-to-beat blood pressure have come
onto the market, including the TaskForce monitor (CN
Systems, Graz, Austria) and Portapres and Finometer systems
(Finapres Medical Systems, Amsterdam, The Netherlands).
These have the advantage of providing derived cardiophysiolo-
gical parameters including stroke volume, cardiac output,
peripheral resistance and, in the case of TaskForce, heart rate
variability and baroreflex sensitivity, though these have yet to
find an accepted place in clinical practice. The test should take
place in a quiet room, at a constant temperature avoiding
excessive heat or cold to avoid autonomic stimulation. The test
should be supervised by an individual (doctor, nurse or
technician) trained in its conduct and capable of managing
potential complications either alone or with previously identi-
fied immediately accessible support (for example, a cardiac
arrest team).
Newcastle protocols 2008: overview and order of testing
Some of the major differences between the previous and current
Newcastle protocols lie in the type, order and conduct of head-
up tilt table testing as summarised in table 1, though all require
the footplate support-type tilt bed and a 70u calibrated tilt
angle. Previously, passive tilt testing was the first line tilt. This
has been replaced by the 20/15 glyceryl trinitrate (GTN) tilt, the
so-called ‘‘Italian protocol’’13 (table 1), now used widely because
of the shorter time to tilt positivity.13 If the patient has had a
previous adverse reaction to nitrates or has suspected psycho-
genic syncope (where nitrate-induced false positivity may serve
only to further confuse the issue), passive (unprovoked) tilt
testing for 40 minutes remains the first-line tilt. If the 20/15 tilt
is negative, and there is still need for a tilt diagnosis, the 20-
minute 800 mg GTN tilt14–16 (‘‘front-loaded GTN head-up tilt’’16)
should be used, though with care regarding a higher propensity
to false positivity.16 The test is short, and has far fewer
contraindications with superior tolerability in all age groups to
isoproterenol provocation, the previous protocols’ second-line
tilt test.1 13–16 While isoproterenol tilt testing has a far larger
evidence base worldwide,2 17 the complications mentioned
above, its poor tolerability (particularly in the elderly),15 side-
effect profile and multiple absolute and relative contraindica-
tions (see original protocols1) make it a third-line choice in our
practice. The previous isoproterenol protocol has been sup-
planted by a shorter test with equal clinical utility18 19 (table 1).
If the front-loaded GTN tilt is negative but a tilt diagnosis is still
thought essential and isoproterenol is impracticable, the joint
third line depending on local availability is lower body negative
pressure (LBNP) tilt testing. The test has only been evaluated in
a small number of patients20 and, indeed, has never been
validated in the older population. None the less, there is a role
for LBNP tilt testing where either a diagnosis has not been
achieved by conventional means or where isoproterenol cannot
be used (see table 1 for details).
Though there has been interest in alternative pharmacological
stimuli to provoke the vasovagal response during tilt testing,
none has been widely validated or gained clinical acceptance.
There has been increasing interest in the use of intravenous
adenosine in the diagnosis of unexplained syncope, but the test
is more likely to provide a proxy-indication for bradycardia
pacing indications than neurally mediated syncope, and is best
regarded as experimental.2 For a more detailed discussion see
Parry et al.21
Positivity criteria
The test is an imperfect one with no gold standard.4 Hence
adherence to the positivity criteria used in all validation studies
is vital—namely, symptom reproduction (usually syncope) in
tandem with the hypotension and/or bradycardia/asystole
characteristic of the vasovagal response. Where haemodynamic
changes occur in the absence of symptom reproduction (or vice
versa), the test is deemed false positive.
NON-VASOVAGAL SYNCOPE RELATED DIAGNOSTIC USES OF
THE HEAD-UP TILT TABLE
The use of the head-up tilt table in the differential diagnosis of
convulsive syncope, postural orthostatic tachycardia syndrome
(POTS),22 orthostatic hypotension (OH)23 and psychogenic and
hyperventilation syncope have been previously described.1
POTS and OH may be diagnosed with appropriate heart rate
and blood pressure monitoring during 2 minutes of active
standing, but tilt-aided diagnosis is mandatory for POTS
diagnosis if the clinical suspicion is high and initial stand
negative. Further advice on POTS investigation and manage-
ment is readily available.22 ‘‘Passive stand’’ during 3-minute tilt
may be helpful where patients have difficulty with active
standing.23 Tilt protocols for POTS and OH are summarised in
table 2.
CAROTID SINUS HYPERSENSITIVITY
The Newcastle protocols for the investigation of carotid sinus
hypersensitivity have changed little since the originals were
published with several important additions. In summary,
carotid sinus massage may be indicated in cases of recurrent
syncope or single episodes of high-risk syncope (for example,
with injury, while driving, occupational imperative), particu-
larly where there is a suggestive history (for example, head
turning, shaving, etc) and in the absence of significant structural
heart disease or ECG abnormality. The test may also be helpful
in the diagnosis of drop attacks7 and unexplained falls,24
particularly where syncope is suspected from the individual or
witness account. We now routinely consent patients for the
procedure, given the remote but potentially devastating
complication of stroke. The risk is approximately 1:1000,25 but
may be higher in those with concomitant cardiovascular and
cerebrovascular co-morbidity. It is clearly important to provide
a balanced view of this risk, with likely benefits from treatment
counterbalancing the remote neurological risks.
During continuous ECG and blood pressure monitoring, the
carotid sinus (maximal point of carotid pulsation between angle
of mandible and superior border of thyroid cartilage) is
massaged longitudinally and firmly for 5 seconds, right side
then left, supine then repeated in the head-up tilt position.26 Up
to a third of diagnoses may be missed if the test is not repeated
upright.26 Test positivity is denoted by >3 seconds asystole
(cardioinhibitory subtype), a fall in systolic blood pressure of
>50 mm Hg (vasodepressor subtype) or both (mixed subtype),
Technology and guidelines
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in tandem with symptom reproduction. This may be inter-
preted differently of course in those with no clear memory of
the event. Some authorities recommend 10 seconds of massage,
though this is not our current practice.1 2
Management of neurally mediated and related disorders
As with the diagnostic process, it can be difficult for the
practising clinician to access succinct, evidence-based guidance
on the management of the neurally mediated disorders. The
following advice is intentionally not a slavish review of the
literature, but reflects our evidence-based day-to-day practice.
Sample references are provided for information.
1. Vasovagal syncope
(a) Immediate action to abort an attack
Tilt testing is particularly valuable in identifying prodromal
symptoms (such as warmth, mild nausea or sweating, ‘‘feeling
odd’’) not previously recognised by the sufferer as heralding a
faint. Early action not only aborts attacks, but seems to shorten
the duration of the profound post-event fatigue many sufferers
experience. Patients should be instructed to perform the
following manoeuvres at the very beginning of symptoms.
c Sit, on the floor with head between drawn-up knees
c Squat, on haunches if able
c Lie, supine elevating the legs as the preferred option.
The last is the most effective way of preventing syncope,
with resumption of normotension from unrecordable blood
pressures in seconds during tilt-induced faints. During these
manoeuvres, and while upright for milder symptoms, physical
counter-pressure manoeuvres should be attempted. There is
now a good evidence base for these strategies,27 which comprise
isometric exercises designed to raise systolic blood pressure,
including forearm tensing and hand clenching, leg crossing and
muscle tensing, and elevating the heels to contract calf muscles
(either when sitting or standing). These manoeuvres require a
sustained contraction with regular breathing.
(b) Longer-term preventive strategies
General measures: Reassurance regarding the benign nature of
the condition and the absence of a ‘‘disease’’ is one of the most
powerful methods of managing vasovagal syncope. Culprit
medications (particularly antihypertensives, anti-anginals, psycho-
active medications, a-blockers and vasodilators) should be
rationalised and discontinued where possible; 24-hour ambulatory
blood pressure monitoring may be helpful in less clearcut cases.
Though there is no evidence base, our clinical experience is that
dihydropyridine calcium channel blockers and angiotensin-con-
verting enzyme (ACE) inhibitors seem less likely to be implicated
in vasovagal syncope. Diuretic and nitrate users seem particularly
prone to faints, though we see a very skewed population in our
secondary and tertiary referral service. Situations provoking
syncope should be avoided or managed with the manoeuvres
suggested above, while compression hosiery (Grade II Duomed
type rather than graduated elasticated stockings, below or above
knee) may be helpful in selected cases. The patient support group
STARS (Syncope Trust and Reflex Anoxic Seizures) provides
useful information and links via its website www.stars.org.uk.
Adequate fluid intake: This strategy alone is highly successful
in reducing the frequency of recurrent faints.28 In recent years,
since promoting this strategy vigorously, our clinic reviews for
vasovagal syncope have plummeted. We advise approximately
1.0–2.0 litres (depending on body habitus, age and co-morbid-
ities) of non-caffeinated fluids (preferably plain water) by lunch-
time, then sufficient fluid intake to keep urine clear. Caffeinated
drinks may be taken in moderation in addition.
Salt supplementation: See below under pharmacological man-
agement.
Cognitive behavioural therapy: Pilot work from our unit29 has
shown enormous benefit from cognitive behavioural therapy,
with therapy being particularly useful in those with anxiety,
depression and ‘‘fear of syncope’’.
Tilt training: Tilt training has recently been shown to be
useful in some patients.2 3 30 The original studies performed
repeated tilt tests on sufferers to induce tolerance and prevent
symptoms.30 Initial studies were promising, but the evidence
Table 1 Head-up tilt testing protocols for the diagnosis of vasovagal syncope
Head-up tilt type
Maximal tilt
duration Protocol
20/15* ‘‘Italian protocol’’13 35 minutes 20 minutes passive tilt, if positivity/discontinuation criteria not reached, 400
mg sublingual GTN administered while upright, continued for further 15
minutes
Front-loaded GTN14 15{ 20 minutes 800-mg sublingual GTN administered supine, tilt for 20 minutes
Isoproterenol18 19 15 minutes Intravenous isoproterenol 0.05 mg/kg/min (to maximum of 5 mg/min)
administered for 5 minutes supine, then 10 minutes tilt.
Discontinue if heart rate .180 bpm, BP.180/110 mm Hg, arrhythmia, chest
pain, intolerable tremulousness, vomiting or other side effects
Lower body negative
pressure20
30 minutes 10 minutes passive tilt, followed by 10 minutes 20 mm Hg suction, followed
by 10 minutes 40 mm Hg suction
All tilts are at 70u using a footplate support-type tilt table, following 10 minutes supine rest (20 minutes post-cannulation for
isoproterenol); tilt termination should be at maximal tilt duration, symptom reproduction with haemodynamic changes consistent
with vasovagal syncope (see text) and/or side/adverse effects and/or patient request.
*Where psychogenic or hyperventilation syncope is suspected, 40-minute passive (non-medicated) tilt should be the sole tilt test.
{The front-loaded GTN head-up tilt may be used as first line where patients are unable to stand for the 35-minute 20/15 tilt.
BP, blood pressure; bpm, beats per minute; GTN, glyceryl trinitrate.
Table 2 Head-up tilt-aided diagnosis of postural orthostatic tachycardia
syndrome and orthostatic hypotension
Description
POTS22 Tilt for 10 minutes; positivity denoted by rise in heart rate of >30 bpm
and/or to >120 bpm
OH23 Tilt for 3 minutes; positivity denoted by sustained fall in SBP
>20 mm Hg or DBP >10 mm Hg
Tilts are at 70u using a foot-plate support-type tilt table, following 10 minutes supine
rest
Test positivity assumes symptom reproduction, though sustained OH in the absence of
symptoms may indicate dysautonomia, addisonism, etc, and require further
investigation and management.
bpm, beats per minute; DBP, diastolic blood pressure; OH, orthostatic hypotension;
POTS, postural orthostatic tachycardia syndrome; SBP, systolic blood pressure.
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base is scanty, while the technique requires considerable
commitment from the patient. An ongoing placebo-controlled
trial of home orthostatic training in our unit may help clarify
these issues. Where attempted, patients should stand against a
wall, with feet approximately 20 centimetres from the wall,
surrounded by a ‘‘drop zone’’ of cushions, etc, for 40 minutes or
until prodromal symptoms supervene, the duration decreasing
over time as symptoms improve. This should be attempted daily
and continued long term.
(c) Pharmacological management
The evidence base for drug treatment of vasovagal syncope is at
best scanty and often contradictory.2 3 31 Pharmacotherapy
should be limited to the few patients with refractory symptoms
following the above conservative measures, with attempted
withdrawal of treatment a year after symptom control is
achieved. Previously used treatments like b-blockers have now
been shown to be of no use in adequately powered randomised
studies,32 while commonly used therapies like fludrocortisone
have no current evidence base, though randomised studies are
under way.33 The following are used in our unit (for contra-
indications (relative and absolute), interactions and side effects
please see the relevant literature):
Fludrocortisone: 50 mg once daily for 1 week, if tolerated increasing
to 100 mg once daily and reviewed after 1 month. The maximum
dose is 300 mg once daily. Supine blood pressure monitoring and
4–6 monthly electrolyte monitoring are mandatory.
Midodrine2 3 31: This a-adrenoceptor agonist has no UK licence,
but can be made available on a named patient basis. We
routinely consent patients for this purpose, with counselling on
expected side effects. Drug information sheets are provided for
the patient and his/her general practitioner. The minimum dose
is 2.5 mg twice daily, rising to a maximum of 15 mg three times
daily in severe cases. The last dose should be given no later than
18.00 given the potential side effect of supine systolic
hypertension. Some patients benefit from as-needed doses
before situations known to precipitate events. Blood test (full
blood count, urea and electrolytes, glucose, bone chemistry,
liver and thyroid function tests) and supine blood pressure
monitoring are vital 4–6 monthly. Combination therapy with
these agents may be needed for some patients. If fludrocortisone
and/or midodrine therapy are continued beyond a year, 24-hour
ambulatory blood pressure monitoring should be undertaken to
look for occult nocturnal hypertension.
Salt supplementation may be used in selected patients with
no contraindications: the few studies available in small numbers
of young patients34 used 120 mmol of salt (as slow sodium, 12
tablets per day in divided doses) daily in patients with 24-hour
urinary sodium estimations of ,170 mmol/24 hour. In our
experience patients are unlikely to tolerate more than 3–4
tablets twice daily because of nausea and vomiting. Blood
pressure should be monitored closely, with discontinuation of
salt therapy attempted after 1 year.
Paroxetine35: In isolated cases, paroxetine (starting at 10 mg once
daily) may be useful in the management of refractory vasovagal
syncope, though we limit its use to patients with concomitant
anxiety and depressive features. Where this is the case, clinical
psychological and/or psychiatric help are sought, and prescription
made only after careful discussion of potential adverse effects.
(d) Permanent pacing
Evidence for the efficacy of permanent pacing in the manage-
ment of vasovagal syncope is contradictory.36 However, we refer
a few patients for pacing per year with the so-called
‘‘malignant’’ vasovagal variant: unheralded, often injurious
vasovagal syncope, with prolonged asystole on tilt testing,
subsequently shown with either external or implantable ECG
monitoring to have .3 seconds asystole during real-time
syncope. Dual chamber pacing is mandatory, preferably DDI
with hysteresis or a specifically designed algorithm for neurally
mediated disorders (for example, rate drop response37 (for
example, Adapta DR, Medtronic Inc), closed loop stimulation38
(for example, Cylos CLS, Biotronik)).
2. Carotid sinus syndrome
General measures per (1a) and (1b) above may be helpful. The
treatment of choice for the cardioinhibitory and mixed subtypes
is permanent pacing using the algorithms previously described.39
Fludrocortisone may be helpful in vasodepressor carotid sinus
syndrome,40 though in our experience this is rarely the sole cause
of syncope. Management is extensively reviewed elsewhere.39
3. Postural orthostatic tachycardia syndrome and orthostatic
hypotension
Again, general measures frequently suffice, though beta-block-
ers can be helpful in POTS.22 Fludrocortisone and midodrine
may be of use in both disorders,22 40 while there is a recent case
report on treating POTS with ivabridine.41 The acetylcholines-
terase inhibitor pyridostigmine42 and the norepinephrine pre-
cursor L-DOPS (L-threo-3,4-dihydroxyserine)43 may be helpful in
selected patients with neurogenic orthostatic hypotension,
though experience is limited.
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